Effectiveness of the available COVID-19 primary and booster vaccination schemes against laboratory-confirmed infections during the different waves. by Rima Moghnieh (679199)

Subjects:

Effectiveness of the available COVID-19 primary and booster vaccination schemes against acute-care hospitalization attributed to laboratory-confirmed infections during the differen... by Rima Moghnieh (679199)

Subjects:

Immunogenicity assessment groups based on the primary and booster vaccination schemes and timeframe from the second or booster dose. by Rima Moghnieh (679199)

Subjects:

Demographic and clinical characteristics of the participants used to estimate effectiveness of the different vaccination schemes during the Omicron BA.4/BA.5 variant wave. by Rima Moghnieh (679199)

Subjects:

Demographic and clinical characteristics of the participants used to estimate effectiveness of the different vaccination schemes during the Alpha variant wave. by Rima Moghnieh (679199)

Subjects:

Demographic and clinical characteristics of the participants used to estimate effectiveness of the different vaccination schemes during the Omicron BA.1/BA.2 variant wave. by Rima Moghnieh (679199)

Subjects:

Fig 4 - by Rima Moghnieh (679199)

Subjects:

Demographic and clinical characteristics of the participants used to estimate effectiveness of the different vaccination schemes during the Delta variant wave. by Rima Moghnieh (679199)

Subjects:

Demographic and clinical characteristics of the participants used to estimate effectiveness of the different vaccination schemes during the mixed Delta and Omicron variant wave. by Rima Moghnieh (679199)

Subjects:

COVID-19 in Lebanon: The daily number of COVID-19 cases throughout the waves of the pandemic in Lebanon and associated SARS-CoV-2 variants between January 2021 and September 2022. by Rima Moghnieh (679199)

Subjects:

Study profile. by Rima Moghnieh (679199)

Subjects:

Fig 3 - by Rima Moghnieh (679199)

Subjects:

SOSV loads in specimens obtained from bats in the SOSV-MARV experimental cohort. by Amy J. Schuh (8520354)

Subjects:

KASV loads in specimens obtained from bats in the KASV-MARV experimental cohort. by Amy J. Schuh (8520354)

Subjects:

Statins resulted in smaller neuronal soma size. by Shuk C. Tsoi (21192243)

“…<p>Soma areas of BrdU + /Hu+ (30 - 32 day old) neurons did not differ between control birds and statin-treated birds, whereas soma areas of the older heterogeneous population of BrdU-/Hu+ neurons were significantly smaller in statin-treated than in control birds (A). …”

Pre- and post-study virus-specific IgG responses for bats in the SOSV-MARV and KASV-MARV experimental cohorts. by Amy J. Schuh (8520354)

Subjects:

The (A) logistic regression model (LRM) and (B) random forest model (RFM) with only conservation scores as independent variables (orange, yellow) show decreased model fitting metri... by Bushra Haque (20513785)

EF-24 treatment significantly reduces cell viability in leukemia cell lines. by Ajeet P. Singh (22298432)

Subjects:

Gentamicin treatment selects for surviving bacteria with reduced S10 expression in the mouse spleen. by Justin Greene (306625)

Subjects:

Weights and body temperatures of bats assigned to the SOSV-MARV and KASV-MARV experimental cohorts. by Amy J. Schuh (8520354)

Subjects: